Mounjaro (tirzepatide) affects both GLP-1 and GIP receptors, raising concerns that its digestive-slowing effects may be stronger or more complex than earlier GLP-1 drugs.
Mounjaro often results in gastrointestinal motility disorders because of the characteristics of the medication that slows down gastric emptying (intestinal transit) leading food to remain in the stomach for a longer than normal time period. This process may result in rare cases of gastroparesis (stomach paralysis). However more common side effects are: constipation, nausea, vomiting, severe stomach pain, and diarrhea. Disorders are usually more problematic in the initial few weeks or following when dosage increases.
- Nearly 22 percent of patients with a Mounjaro script suffer through nausea,
- diarrhea (11–17%),
- vomiting, and constipation (4–10%).
Motility Disorders Reported With Mounjaro
Patients have reported:
- gastroparesis
- severe constipation
- ileus
- generalized GI dysmotility
Dual-Action Mechanism Concerns
Mounjaro’s dual hormone action may:
- intensify
- further slow GI transit
- disrupt gut-brain signaling
In some patients, this appears to lead to prolonged or severe motility impairment.
Common Symptoms
- persistent nausea and vomiting
- inability to eat normally
- abdominal pain and distension
- dehydration
Legal Context
Mounjaro motility disorder claims focus on:
- severity of digestive injury
- permanence of symptoms
- failure to warn of extreme motility suppression
➡️ Related: Motility Disorders
Mounjaro-related motility disorders can result in long-term digestive disability. These injuries are now actively evaluated within GLP-1 litigation.